Pooled evidence suggested that topical anaesthetic creams ( TAs ) , tramadol , selective serotonin reuptake inhibitors ( SSRIs ) , and phosphodiesterase type 5 inhibitors ( PDE5is ) are more effective at prolonging IELT comparing with placebo .
Conclusions We recommend the initial use of dapoxetine 30 mg OD for PE because it has been tested in largest and better design ed clinical trials rather than it is more effective than the other drugs studied .
TAs and tramadol 50 mg OD can be used as a viable alternative to oral treatment with SSRIs .
PDE5is combined with SSRIs are more effective than SSRIs monotherapy but are also associated with more side effects .
Purpose The purpose of the study was to conduct a systematic evaluation of the different general prescribed drugs for  premature ejaculation ( PE ) .
A randomized double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of two doses of the tramadol orally disintegrating tablet for the treatment of premature ejaculation within less than 2 minutes.
BACKGROUND  Premature ejaculation ( PE ) is a widely observed male sexual dysfunction with a major impact on quality of life for many men and their sexual partners . OBJECTIVE To assess the safety of tramadol orally disintegrating tablet ( ODT ) ( Zertane ) and its efficacy in prolonging intravaginal ejaculation latency time ( IELT ) and improving Premature Ejaculation Profile ( PEP ) scores . DESIGN , SETTING , AND PARTICIPANTS We conducted an integrated analysis of two identical 12-wk r and omized double-blind , placebo-controlled phase 3 trials across 62 sites in Europe . Healthy men 18 - 65 yr of age with a history of lifelong PE according to the Diagnostic and Statistical Manual of Mental Disorders , 4th Edition , Text Revision , and an IELT ≤ 120 s were included . There were 604 intent-to-treat subjects included in the analysis . INTERVENTION Subjects were r and omized to receive 1:1:1 placebo ( n=200 ) , 62 mg tramadol ODT ( n=206 ) , or 89 mg tramadol ODT ( n=198 ) . MEASUREMENTS We measured overall change and fold increase in median IELT and the mean change in all four measures of the PEP . Differences across treatment groups were analyzed using Wilcoxon rank-sum tests , analysis of variance , and chi-square analyses . RESULTS AND LIMITATIONS Tramadol ODT result ed in significant increases in median IELT compared with placebo ; increases were 0.6 min ( 1.6 fold ) , 1.2 min ( 2.4 fold ) , and 1.5 min ( 2.5 fold ) for placebo , 62 mg tramadol ODT , and 89 mg tramadol ODT , respectively ( p<0.001 for all comparisons ) . Men saw significantly greater improvement in all four measures of the PEP in both doses compared with placebo ( p<0.05 for all comparisons ) . Tramadol ODT was well tolerated ; study discontinuation occurred in 0 % , 1.0 % , and 1.6 % of subjects in placebo , 62 mg , and 89 mg tramadol ODT groups , respectively . Limitations include study inclusion for men with IELT up to 120 s. CONCLUSIONS On-dem and 62 mg tramadol ODT is an effective treatment for PE in a low and safe therapeutic dose and provides a new option for managing mild to severe PE
Pooled evidence suggested that topical anaesthetic creams ( TAs ) , tramadol , selective serotonin reuptake inhibitors ( SSRIs ) , and phosphodiesterase type 5 inhibitors ( PDE5is ) are more effective at prolonging IELT comparing with placebo .
Conclusions We recommend the initial use of dapoxetine 30 mg OD for PE because it has been tested in largest and better design ed clinical trials rather than it is more effective than the other drugs studied .
TAs and tramadol 50 mg OD can be used as a viable alternative to oral treatment with SSRIs .
PDE5is combined with SSRIs are more effective than SSRIs monotherapy but are also associated with more side effects .
Purpose The purpose of the study was to conduct a systematic evaluation of the different general prescribed drugs for  premature ejaculation ( PE ) .